Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hormone-refractory prostate cancer].

I Alexandre1, O Rixe

  • 1Service d'oncologie médicale, groupe hospitalier Pitié-Salpêtrière, Assistance Publique, Hôpitaux de Paris, 41-87, boulevard de l'Hôpital, 75013 Paris, France.

Annales D'Urologie
|May 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2014
Same author

A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer.

Cancer chemotherapy and pharmacology·2012
Same author

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

British journal of cancer·2012
Same author

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

[Initial management in oncology: results of CPRIM surveys on 2,583 patient's perceptions and expectations (outside Anticancer Centers)].

Bulletin du cancer·2010
Same author

[New therapeutics strategies in renal cell carcinoma].

Bulletin du cancer·2010
Same journal

Prostate cancer at the 2007 ASCO meeting: an urologist's perspective.

Annales d'urologie·2008
Same journal

[Surgical treatment of ureteropyelic junction stenosis using robotic-assisted laparoscopy].

Annales d'urologie·2008
Same journal

[Robotic-assisted laparoscopy: general principles].

Annales d'urologie·2008
Same journal

[De novo tumours of renal transplants].

Annales d'urologie·2008
Same journal

[Immunosuppression in kidney transplantation].

Annales d'urologie·2008
Same journal

[Surgical complications in kidney transplantation].

Annales d'urologie·2008
See all related articles

Advanced hormone-refractory prostate cancer has poor prognosis. Recent chemotherapy advances, including docetaxel combinations, show promising efficacy and low toxicity, improving survival and symptoms for metastatic prostate cancer patients.

Area of Science:

  • Oncology
  • Medical Treatment

Background:

  • Hormone-refractory prostate cancer (HRPC) represents an advanced stage of metastatic prostate cancer.
  • HRPC is characterized by a poor prognosis and limited median survival, typically 9 to 18 months.

Purpose of the Study:

  • To review prognostic factors and medical treatments for HRPC.
  • To focus on recent advancements in chemotherapy for HRPC management.

Main Methods:

  • Literature review of prognostic factors and medical treatments for HRPC.
  • Analysis of recent clinical protocols and chemotherapy advancements.

Main Results:

  • Docetaxel improves median survival and symptoms in HRPC patients.
  • New protocols combining docetaxel with calcitriol or antiangiogenic agents show promising results.

Related Experiment Videos

  • Supportive care is crucial due to significant bone involvement.

    • Conclusions:

    • Recent pharmacological combinations represent significant progress in HRPC management.
    • These advancements offer promising efficacy with minimal toxicity.
    • Improved survival and symptom management are key outcomes for HRPC patients.